
|Articles|December 15, 2002
Phakic IOLs offer promise from a U.S. surgeon's perspective
In a recent Market Scope report onphakic IOLs, editor David Harmon observes: "Phakic IOLs have become a standard part of the European ophthalmologist's tool kit. CE Mark regulatory approval has been granted to four manufacturers of the devices . . . Europe has become the center of worldwide phakic IOL clinical experience . . . European surgeons implanted an estimated 15,350 phakic IOLs last year."
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5

















































.png)


